Seminar on the launch of NISSEIKEN products (AP125RX, APM, ARBP-ME, MPS)
in Vietnam
On 25 June 2024, Nisseiken Company Limited (NISSEIKEN), a Japanese subsidiary, and Tien Thang
Service and Trading Development Company Limited (TSD, one of Charoen Pokphand Group Co., Ltd.),
the sole distributor of NISSEIKEN products in Vietnam, held a seminar for the launch of NISSEIKEN
products (AP125RX, APM, ARBP-ME, MPS) in Vietnam. The products were jointly launched at a seminarin Ho Chi Minh City. The seminar was covered by a local trade magazine “Channuoi Vietnam” andpublished on its website the following day.
NISSEIKEN will continue to value customer feedback and committed to providing a stable effective andsafe Japanese vaccines domestically and internationally.
Below is a provisional English translation of the Channuoi Vietnam magazine website where it appeared.
URL Source: Ra mắt vắc xin AP125RX phòng bệnh viêm màng phổi trên heo bằng công nghệ Nhật Bản- Tạp chí Chăn nuôi Việt Nam (nhachannuoi.vn)
ｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰｰ

Launching of “AP125RX”, a vaccine for the prevention ofpleuropneumonia in pigs using Japanese technology.
On June 25, 2024, in Ho Chi Minh City, Nisseiken Co, Ltd. (Japan), and Tien Thang Service and Trading
Development Company Limited (TSD) successfully launched its new vaccine to start the workshop theme: Situationof respiratory diseases in pigs and solutions for the future with Japanese technology.

Seminar overview

During the opening remarks, Shinya Nagai, President of Nisseiken Co. Ltd., emphasized that the AP125RX vaccine
an excellent vaccine that was given an award by the Japanese Ministry of Agriculture, Forestry, and Fisheries. The
development and efficacy of the award-winning vaccine has led to pig pleuropneumonia no longer being a serious
problem in Japan.
"This launch, therefore, marks an important milestone for our company as we continue to strengthen and expand ourpresence in the Vietnamese market. Vietnam is a country with great potential and dynamic growth. We are proud tobe part of this dynamic economy and to contribute to the further development of Vietnam's livestock industry throughour innovative products," emphasized Dr. Shinya Nagai.
According to Dr. Shinya Nagai, the purpose of today's seminar is not only to introduce new products, but also toshare Nisseiken's vision for the future of the company as well as "Nisseiken's value creation for customers, partners,
and the community. I am confident that as we begin this new journey, together with Advance Pharma Vietnam (APV)and TSD, we will achieve great success and create a bright future for Vietnam's livestock industry," said Dr. ShinyaNagai.

Dr. Shinya Nagai, President of Nisseiken Co., Ltd.
Also at the workshop, Mr. Vo Viet My, Sales Director of TSD shared that in the recent past, thanks to the support ofvalued customers and partners, the support of agents, and the great efforts of all employees, we have achieved manysuccesses and enhanced our position in the Vietnamese market.
“The workshop aims to update the industry on the situation of swine diseases in Vietnam and at the same time,provide optimal solutions for customers. On this occasion, the company also would like to express gratitude to all ofits partners, customers, officers and employees who have accompanied us. This is also a milestone marking the strong
development of the Company and the continued development in the following years,” said Mr. Vo Viet My.

Dr. Vo Vet My, TSD sales director
During at the seminar, Associate Professor, Dr. Do Tien Duy, Deputy Head of the Animal Biomedical ResearchLaboratories, Senior lecturer of Infectious Diseases and Veterinary Public Health, Faculty of Animal Science
Husbandry and Veterinary Medicine, Nong Lam University, Ho Chi Minh City, shared the current situation ofrespiratory diseases in pigs in Vietnam. According to Associate Professor, Dr. Do Tien Duy, the weaning stage is themost sensitive stage for the health and growth of pigs. At this stage, pigs are affected by many stress factors, maternal
immunity in pigs is reduced... creating conditions for the development of opportunistic pathogens that may have been
infected in the respiratory tract during the piglet stage, increasing the possibility of respiratory diseases in pigs afterweaning.
Associate Professor, Dr. Do Tien Duy explained that “respiratory diseases in pigs often occur during the weaningstage, due to infection with pathogenic microorganisms from sows and the poor immune status of piglets during theweaning stage. Therefore, to effectively control respiratory diseases in weaned pigs, it is necessary to control risk
factors well from the nursing stage and then in the post-weaning stage,”

Dr. Do Tien Duy, Associate professor
Also at the workshop, Dr. Natsumi, senior product manager of NISSEIKEN, shared information about the AP125RX

and APM products. “APP pneumonia and pleurisy are common in pigs and occur at 60-70 days of age. Acutesymptoms include respiratory failure and sudden death, while chronic symptoms include slower growth and persistent
cough. The World Health Organization issued a warning regarding the emergence of pathogen strains that are resistantto antibiotics is a global concern.
Dr. Natsumi stated that “Antibiotics have been conventionally used to prevent and treat APP. However, disease
prevention through vaccination is a growing trend and is replacing the use of antibiotics as a treatment and prevention
measure. We should not use antibiotics on healthy pigs but instead increase the use of vaccines to prevent common
diseases in conjunction with biosecurity”
According to Dr. Natsumi, one of the pathogenic factors of APP is toxins. Therefore, the product AP125RX utilizes
6 antigens that control APP which include: firstly, the 3 APP serotype antigens (1, 2, 5) and secondly, the 3
recombinant toxins (rApx I, rApx II, rApx III) of APP to create antibodies. This allows pigs to recognize these nontoxic recombinant toxins as antigens and generate an appropriate immune response. The use of both bacterin andtoxin antigens will produce a more complete vaccination effect.

Dr. Natsumi Takeyama, Nisseiken Co., Ltd.
APM is a product that combines six antigens of AP125RX and one antigen of M. hyopneumoniae and can be used as
an alternative solution on farms.

TSD representatives presented gifts to the guests.